CatenaBio Selected to Present on its Next Generation Platform and Multi Payload Conjugates (MPC®) at the Berkeley Bio Startup Showcase @JPM
CatenaBio was founded to develop novel therapeutics by forming never-before-possible structures enabled by its proprietary technology, which can modify and combine proteins with unmatched selectivity.
- CatenaBio was founded to develop novel therapeutics by forming never-before-possible structures enabled by its proprietary technology, which can modify and combine proteins with unmatched selectivity.
- The company’s CysTyr® platform utilizes the novel Catenase® enzyme, engineered to selectively attach tyrosine residues with cysteine residues to form the proprietary C-Y Bond®.
- Catena is developing a first-in-class pipeline of Multi Payload Conjugates (MPC®) to deliver targeted combination therapies designed to overcome tumor resistance and potentially lead to superior efficacy and toxicity profiles.
- Tested in vitro across multiple HER2+ cell lines, the MPCs® demonstrated improved efficacy compared to the current standard of care, DS8201a (T-DXd).